Results of the High dose arm of the Phase I/II Mexico City Trial (2 shots at days 10 and 28 after doctor�s visit with symptoms).

After one year of observation, the AuRx therapy was found to completely block recurrent disease in 43.5% of the treated patients treated while only 13% of the placebo group were free of recurrences. 61% of the treated patients had 2 or less recurrences where they had experienced an average of 8.5 recurrences the previous year. The number of recurrent episodes relative to previous year was reduced 3 fold (P<0.001).

Overall, there was a 2 fold reduction in episodes/patient in treated vs. placebo group in a statistically significant result - an average of 2.52 episodes per treated patient vs 4.8 in the placebo group.

Results of the Low dose arm of the Phase I/II Mexico City Trial (3 shots at days 7, 17 and 28 after doctor�s visit with symptoms) after 6 months observation.

During the first six months after the inoculations, recurrences in the treated group were prevented completely in 37.5% of the patients, whereas in the placebo group, 100% of the patients had at least one recurrence. Treated patients had 50% fewer recurrences and this result was statistically significant. Itching, vesicles, pain, ulcers, painful urination, and burning in the genital area were also reduced significantly.